AAC Pharmacological Interventions 3

Question 1

Which antipsychotic carries an FDA black box warning specifically for increased mortality risk when used in elderly patients with dementia-related psychosis?

Accepted Answer

All antipsychotics, both typical and atypical

Answer

The FDA black box warning applies to all antipsychotic medications—both typical and atypical—regarding increased mortality in elderly patients with dementia-related psychosis.

Question 2

A person with Alzheimer's develops severe agitation during late-afternoon hours daily. Before considering pharmacological treatment, the standard guideline-recommended first step is:

Accepted Answer

Identify and address potential non-pharmacological triggers

Answer

Guidelines consistently recommend non-pharmacological interventions as first-line treatment for behavioral symptoms before considering medications.

Question 3

Tacrine (Cognex) was the first FDA-approved cholinesterase inhibitor for Alzheimer's but is no longer used primarily because of:

Accepted Answer

Serious hepatotoxicity requiring frequent liver monitoring

Answer

Tacrine was withdrawn from clinical use due to significant hepatotoxicity, with patients requiring frequent liver function monitoring.

Question 4

When discontinuing a cholinesterase inhibitor after long-term use, the recommended approach is:

Accepted Answer

Gradual tapering over several weeks

Answer

Abrupt discontinuation of cholinesterase inhibitors can cause rapid cognitive or behavioral decline; gradual tapering is recommended to minimize this risk.

Question 5

Which medication class should generally be AVOIDED in Alzheimer's patients because anticholinergic effects can worsen cognitive function?

Accepted Answer

First-generation antihistamines like diphenhydramine

Answer

Anticholinergic medications like diphenhydramine block the acetylcholine system, directly counteracting cholinesterase inhibitor therapy and worsening cognition.

(AAC) Alzheimer's Association Certification Practice Test

(AAC) Alzheimer's Association Certification Practice Test

AAC Pharmacological Interventions 3